東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Expression of Free Fatty Acids and T...

Al-Hadlaq, Malak Adel,

FindBook

Google Book

Amazon

博客來

Expression of Free Fatty Acids and Their Receptors on Oral Neutrophils in Oral Lichen Planus /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Expression of Free Fatty Acids and Their Receptors on Oral Neutrophils in Oral Lichen Planus // Malak Adel Al-Hadlaq.
作者:	Al-Hadlaq, Malak Adel,
面頁冊數:	1 electronic resource (97 pages)
附註:	Source: Dissertations Abstracts International, Volume: 85-11, Section: B.
Contained By:	Dissertations Abstracts International85-11B.
標題:	Immunology. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31242299
ISBN:	9798382405742

Expression of Free Fatty Acids and Their Receptors on Oral Neutrophils in Oral Lichen Planus /
Al-Hadlaq, Malak Adel,

Expression of Free Fatty Acids and Their Receptors on Oral Neutrophils in Oral Lichen Planus /Malak Adel Al-Hadlaq. - 1 electronic resource (97 pages)

Source: Dissertations Abstracts International, Volume: 85-11, Section: B.

Objectives: The aim of this project is to assess expression of specialized pro-resolving lipid mediators (SPMs) and inflammation resolution receptors on oral neutrophils (oPMNs) in oral lichen planus (OLP) compared to healthy controls. FFAR2 binds short chain fatty acids, FFAR4 binds long chain fatty acids, ERV1 binds Resolvin E1, and ALX binds Lipoxin A4. We hypothesize that in OLP, there is decreased oPMN surface expression of inflammation resolution receptors and decreased levels of SPMs, reflecting a failure of the distinct process of inflammation resolution, and hence progression from acute to chronic inflammation in the disease pathogenesis. SPMs activate the inflammation resolution pathways and are potential therapeutic options, especially for steroid refractory OLP.Methods: OLP cases and healthy controls were recruited from the oral medicine clinic at Brigham and Women's Hospital and the Harvard School of Dental Medicine. Oral rinse samples were collected for oPMN isolation and lipidomics analysis using liquid chromatography-tandem mass spectrometry. oPMNs were labeled and analyzed by flow cytometry. The number/percentage of cells positive for inflammation resolution receptors, quantities of receptors per cell, and levels of lipid mediators of inflammation were compared using two-sample t-tests. Principle component analysis (PCA) was performed to identify clustering trends in lipid profiles and exploratory biomarker analysis was conducted to identify potential salivary biomarkers for OLP.Results: A total of 27 healthy controls and 17 OLP cases were included. Cases had almost double the number of mean total oPMNs (14x103, p<0.01) and viable (CD16+) oPMNs (8x103, p=0.01). The mean percentage of ERV1+ oPMNs was higher in cases than controls (84% vs. 67%, p<0.01). The mean fluorescent intensity (MFI) for receptors in cases vs controls were: 63x103 vs. 90x103 for ERV1 (p<0.01), 83x103 vs. 66x103 for FFAR2 (p=0.02), 53x103 vs. 36x103 for FFAR4 (p=0.02), and 604x103 vs. 690x103 for ALX (p=0.45). Overall, pro-inflammatory lipid mediators were upregulated while pro-resolving lipid mediators were downregulated in OLP cases compared to controls. PCA identified that the lipid mediator profiles were generally different between the two groups by the distinct clustering of samples. Prostaglandin F2 alpha (PGF2α) and 20-hydroxy leukotriene B4 (LTB4) had significantly higher levels in cases and showed good discriminatory potential as biomarkers for OLP.Conclusion: In OLP, there were more ERV1+ oPMNs, but less expression of ERV1. There is variation in the lipid mediator profiles between cases and controls, with downregulation of pro-resolution mediators in OLP. These findings possibly indicate a failure of inflammation resolution in OLP, and potentially explain acute/symptomatic exacerbations of this chronic condition. Further research is required to support translational studies using topical preparations of SPMs in the management of OLP.

English

ISBN: 9798382405742Subjects--Topical Terms:

611031
Immunology.
Subjects--Index Terms:

Inflammation

Expression of Free Fatty Acids and Their Receptors on Oral Neutrophils in Oral Lichen Planus /
LDR:04483nmm a22004213i 4500 001 2438208
005 20251210113945.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798382405742
035 $a (MiAaPQD)AAI31242299
035 $a AAI31242299
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Al-Hadlaq, Malak Adel, $e author. $0 (orcid)0009-0007-0048-5406 $3 3829445
245 1 0 $a Expression of Free Fatty Acids and Their Receptors on Oral Neutrophils in Oral Lichen Planus / $c Malak Adel Al-Hadlaq.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (97 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-11, Section: B.
500 $a Advisors: Van Dyke, Thomas; Sima, Corneliu Committee members: Kantarci, Alpdogan; Sroussi, Herve; Ikeda, Kentaro.
502 $b D.M.Sc. $c Harvard University School of Dental Medicine $d 2024.
520 $a Objectives: The aim of this project is to assess expression of specialized pro-resolving lipid mediators (SPMs) and inflammation resolution receptors on oral neutrophils (oPMNs) in oral lichen planus (OLP) compared to healthy controls. FFAR2 binds short chain fatty acids, FFAR4 binds long chain fatty acids, ERV1 binds Resolvin E1, and ALX binds Lipoxin A4. We hypothesize that in OLP, there is decreased oPMN surface expression of inflammation resolution receptors and decreased levels of SPMs, reflecting a failure of the distinct process of inflammation resolution, and hence progression from acute to chronic inflammation in the disease pathogenesis. SPMs activate the inflammation resolution pathways and are potential therapeutic options, especially for steroid refractory OLP.Methods: OLP cases and healthy controls were recruited from the oral medicine clinic at Brigham and Women's Hospital and the Harvard School of Dental Medicine. Oral rinse samples were collected for oPMN isolation and lipidomics analysis using liquid chromatography-tandem mass spectrometry. oPMNs were labeled and analyzed by flow cytometry. The number/percentage of cells positive for inflammation resolution receptors, quantities of receptors per cell, and levels of lipid mediators of inflammation were compared using two-sample t-tests. Principle component analysis (PCA) was performed to identify clustering trends in lipid profiles and exploratory biomarker analysis was conducted to identify potential salivary biomarkers for OLP.Results: A total of 27 healthy controls and 17 OLP cases were included. Cases had almost double the number of mean total oPMNs (14x103, p<0.01) and viable (CD16+) oPMNs (8x103, p=0.01). The mean percentage of ERV1+ oPMNs was higher in cases than controls (84% vs. 67%, p<0.01). The mean fluorescent intensity (MFI) for receptors in cases vs controls were: 63x103 vs. 90x103 for ERV1 (p<0.01), 83x103 vs. 66x103 for FFAR2 (p=0.02), 53x103 vs. 36x103 for FFAR4 (p=0.02), and 604x103 vs. 690x103 for ALX (p=0.45). Overall, pro-inflammatory lipid mediators were upregulated while pro-resolving lipid mediators were downregulated in OLP cases compared to controls. PCA identified that the lipid mediator profiles were generally different between the two groups by the distinct clustering of samples. Prostaglandin F2 alpha (PGF2α) and 20-hydroxy leukotriene B4 (LTB4) had significantly higher levels in cases and showed good discriminatory potential as biomarkers for OLP.Conclusion: In OLP, there were more ERV1+ oPMNs, but less expression of ERV1. There is variation in the lipid mediator profiles between cases and controls, with downregulation of pro-resolution mediators in OLP. These findings possibly indicate a failure of inflammation resolution in OLP, and potentially explain acute/symptomatic exacerbations of this chronic condition. Further research is required to support translational studies using topical preparations of SPMs in the management of OLP.
546 $a English
590 $a School code: 2122
650 4 $a Immunology. $3 611031
650 4 $a Dentistry. $3 828971
650 4 $a Pathology. $3 643180
653 $a Inflammation
653 $a Oral lichen planus
653 $a Resolution receptors
690 $a 0982
690 $a 0567
690 $a 0571
710 2 $a Harvard University School of Dental Medicine. $b Oral Medicine. $e degree granting institution. $3 3829446
720 1 $a Van Dyke, Thomas $e degree supervisor.
720 1 $a Sima, Corneliu $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 85-11B.
790 $a 2122
791 $a D.M.Sc.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31242299